Serotonin sendromu

Serotonin sendromu periferde ve santral sinir sisteminde bulunan serotonin (5-hidroksi triptamin; 5-HT) reseptörlerinin aşırı uyarılması sonucu gelişir. Klinik bulgular mental durum değişiklikleri, otonomik disfonksiyon ve nöromusküler uyarılmadan oluşan bir triadı içerir. Serotonerjik etkili bir veya daha fazla ilacın bir arada kullanılması bu sendroma yol açar. Serotonin sendromu anestezide kullanılan meperidin, fentanil ve tramadol gibi ilaçlarla daha karmaşık bir hale gelebilir. Olguların büyük bir kısmı hipertermi ve otonomik disfonksiyonu önleyici destek ve semptomatik tedavi ile düzelirken, ağır olgularda yoğun bakım ve mekanik ventilasyon gereksinimi söz konusudur.

Serotonin syndrome

Serotonin syndrome results from excessive activation of serotonin (5- hydroxytryptamine; 5-HT) receptors peripherial and central nervous system. The clinical manifestations are a triad of altered mental status, otonomic dysfunction and neuromuscular exitability. The syndrome caused by the administration of one or more drugs having serotonergic activity. Serotonin syndrome may complicate the administration of drugs used in anesthetic practice, including meperidine, fentanyl and tramadol. Although the majority of cases improve with symptomatic and supportive care to treat hypertermia and autonomic dysfunction, severe cases need intensive care and require mechanical ventilation.

PDF

___

1. Anaesth Intensive Care 2005; 33: 181- 187.
2. Bijl D. The serotonin syndrome. Neth J Med 2004; 62: 309 - 313.
3. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 11: 1112 -1123.
4. Eadie MJ. Convulsive ergotizm: epidemics of the serotonin syndrome? Lancet Neurol 2003; 2: 429 - 434.
5. Ganetsky M, Brush E. Serotonin syndrome: what have we learned? Clin Pediatr Emerg Med 2005; 6: 103 - 108.
6. Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28: 520 - 526.
7. Oates JA, Sjoerdsma A. Neurologic effects of tryrtophan in patients receiving a monoamino oxidase inhibitor. Neurology 1960; 10: 1076 - 1077.
8. Smith B, Prockop DJ. Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. NEJM 1962; 267:1338 - 1341.
9. Özdemir S, Kocabaşoğlu N. Serotonin sendromuna güncel bir yaklaşım. Klinik Psikofarmakoloji Bülteni 2007; 17: 217 - 225.
10. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635 - 642.
11. Goldberg RJ. Selective serotonin reuptake inhibitors. Arch Fam Med 1998; 7: 78 - 84.
12. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol 2004; 42: 277 - 285.
13. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21: 353 - 421.
14. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999; 49: 871 - 874.
15. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999; 33: 457 - 459.
16. Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal 2001; 85: 147 - 148.
17. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720 -726.
18. De Ponti F. Pharmacology of serotonin: What a clinician should know. Gut 2004; 53: 1520 - 1535.
19. Caplin ME; Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carsinoid tumour. Lancet 1998; 352: 799 - 805.
20. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705 - 713.
21. Isbister GK, Whyte IM. Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. Br J Anaesth 2002; 88: 603 - 604.
22. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin 5-HT2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001; 890: 23 - 31.
23. Garside S, Rosebuch PI. Serotonin syndrome: not a benign toxidrome. CMAJ 2003; 16: 543.
24. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003; 36: 1197.
25. Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, Dhimes Tejada P. Serotonin syndrome: report a fatal case and review of the literature. Rev Clin Esp 2002; 202: 209 - 211.
26. Dams R, Benijts TH, Lambert WE et al. A fatal case of serotonin syndrome after combined moclobenidcitalopram intoxication. J of Anal Toxicol 2001; 25: 147 - 151.
27. Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J. Severe serotonin syndrome induced by mirtazapine monotheraphy. Ann Pharmacother 2002; 26: 641 -643.
28. Miller F, Friedman R, Tanenbaum J, Griffin A. Disseminated intravascular coagulşation and acute myoglobinuuric renal failure: a consecuence of the serotonin syndrome. J Clin Psycopharmacol 1991; 11: 277 - 279.
29. Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 2004;37: 57 - 62.
30. Done CJ, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5- HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994; 33: 411- 421.
31. Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 2003; 43: 155 - 164.
32. Beier MT. The serotonin syndrome revisited. J Am Med Dir Assoc 2005; 6: 281.
33. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003; 168: 1439 - 1442.
34. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997; 13: 763 - 783.
35. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79: 201 - 209.
36. Dursun SM, Burke JG, Reveley MA. Toxic serotonin syndrome or extrapyramidal side-effects? Br J Psychiatry 1995; 166: 401 - 402.
37. Radomski JW, Dursun SM, Reveley MA. Toxic serotonin syndrome (TSS): an update and revised diagnostic criteria. J Psychopharmacol 1995; 9: 83.
38. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55: 218 - 224.
39. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. MJA 2007; 187: 361 - 365.
40. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36: 67 - 71.
41. Bower EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112-1120.
42. Mahajan R, Gupta R, Sharma A. Management of serotonin syndrome. Anaesth Intensive Care 2005; 33: 822.
43. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with ciproheptadine. J Emerg Med 1998; 16: 615 - 619.
44. Gillman PK. The serotonin syndrome and its treatment. J Psycopharmacol 1999; 13: 100 - 109.
45. Ganetsky M, Babu KM, Boyer EW. Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy. Pediatr Emerg Care 2007; 23: 829 - 831.
46. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95: 434 - 441.
47. Tao R, Karnik M, Ma Z, Auerbach SB. Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors. Br J Pharmacol 2003; 139: 1498 - 1504.
48. Giese SY, Neborsky R. Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl. Plast Reconstr Surg 2001; 107: 293 - 294.
49. Turkel SB, Nadala JGB, Wincor ZM. Possible serotonin syndrome in association with 5- HT3 antagonist agents. Psychosomatics 2001; 42: 258 - 260.
50. Ozkardesler S, Gurpinar T, Akan M et al. A possible perianesthetic serotonin syndrome related to intrathecal fentanyl. J Clin Anesth 2008; 20: 143 - 145.
51. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother 2006; 40: 155 - 157.
52. Ure DS, Gillies MA, James KS. Safe use of remifentanil in a patient treated with the mono amino oxidase inhibitor phenelzine. Br J Anaesth 2000; 84: 414 - 416.
53. Hunter B, Kleinert MM, Osatnik J, Soria E. Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil? Anesth Analg 2006;102:1585- 1598.
54. Bach KK, Lindsay FW, Berg LS, Howard RS. Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg 2004; 99: 1573 -
1574. 55. Siebert C, Kroeber S, Lutter N. Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg 2005; 101: 608 - 609.
56. Khan M, North AP, Chadwick DR. Prolonged postoperative altered mental status after methylene blue infusion during parathyroidectomy: a case report and review of the literature. Ann R Coll Surg Engl 2007; 89: 1 - 3.
57. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psycopharmacol 1999; 13: 313 - 317.